IL238727A0 - Mucosal administration of tocotrienol - Google Patents

Mucosal administration of tocotrienol

Info

Publication number
IL238727A0
IL238727A0 IL238727A IL23872715A IL238727A0 IL 238727 A0 IL238727 A0 IL 238727A0 IL 238727 A IL238727 A IL 238727A IL 23872715 A IL23872715 A IL 23872715A IL 238727 A0 IL238727 A0 IL 238727A0
Authority
IL
Israel
Prior art keywords
tocotrienol
transmucosal delivery
transmucosal
delivery
Prior art date
Application number
IL238727A
Other languages
English (en)
Hebrew (he)
Original Assignee
Gordagen Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904937A external-priority patent/AU2012904937A0/en
Application filed by Gordagen Pharmaceuticals Pty Ltd filed Critical Gordagen Pharmaceuticals Pty Ltd
Publication of IL238727A0 publication Critical patent/IL238727A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL238727A 2012-11-13 2015-05-10 Mucosal administration of tocotrienol IL238727A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Publications (1)

Publication Number Publication Date
IL238727A0 true IL238727A0 (en) 2015-06-30

Family

ID=50730398

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238727A IL238727A0 (en) 2012-11-13 2015-05-10 Mucosal administration of tocotrienol

Country Status (22)

Country Link
US (2) US10675265B2 (enExample)
EP (1) EP2919777B1 (enExample)
JP (3) JP6460998B2 (enExample)
KR (1) KR20150082109A (enExample)
CN (2) CN104582700B (enExample)
AU (1) AU2013344817B2 (enExample)
BR (1) BR112015010703B1 (enExample)
CA (1) CA2891164C (enExample)
DK (1) DK2919777T3 (enExample)
ES (1) ES2778065T3 (enExample)
IL (1) IL238727A0 (enExample)
IN (1) IN2015DN04006A (enExample)
MY (1) MY177940A (enExample)
NZ (1) NZ628963A (enExample)
PE (1) PE20151518A1 (enExample)
PH (1) PH12015501048A1 (enExample)
PL (1) PL2919777T3 (enExample)
PT (1) PT2919777T (enExample)
RU (1) RU2015120181A (enExample)
SG (1) SG11201503640WA (enExample)
WO (1) WO2014075135A1 (enExample)
ZA (1) ZA201504191B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
RU2015120181A (ru) * 2012-11-13 2017-01-10 Гордаген Фармасьютикалз Пти Лтд Чресслизистая доставка токотриенола
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2017025808A1 (en) * 2015-08-11 2017-02-16 Satoru Sugiyama System and method for improved blood circulation and maintaining mitochondrial energy production
EP3337402A4 (en) 2015-08-20 2019-04-24 Aseko, Inc. THERAPY ADVISOR FOR DIABETES MANAGEMENT
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
US20240139100A1 (en) * 2020-12-04 2024-05-02 Invictus Biotechnology Pty Ltd Transmucosal delivery of tocotrienols

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124086A1 (en) * 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
JPH0892050A (ja) 1994-09-27 1996-04-09 Lion Corp 消臭剤及び口腔用組成物
JP4271742B2 (ja) 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫機能改善剤
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6864280B2 (en) * 2000-03-31 2005-03-08 Eisai Co., Ltd. γ-Tocotrienol-containing diuretics
JP2001342133A (ja) 2000-03-31 2001-12-11 Eisai Co Ltd γ―トコトリエノール含有利尿剤
JP2002037727A (ja) 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
JP4693140B2 (ja) 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
JP4447198B2 (ja) 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びfgf阻害剤並びに食品或いは食品添加物
US6608103B2 (en) * 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
WO2004086412A2 (en) 2003-02-14 2004-10-07 Henry M. Jackson Foundation For The Advancement Of Military Medecine, Inc. Radiation protection by gamma-tocotrienol
CA2521020C (en) * 2003-04-10 2021-04-27 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
US20060013901A1 (en) * 2004-05-26 2006-01-19 Kgk Synergize Inc. Compositions comprising flavonoids and tocotrienols and methods thereof
CN1775289B (zh) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 多维生素口腔崩解片制剂及其制备方法
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009126866A2 (en) * 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
MX2011012078A (es) 2009-05-20 2012-03-14 Lingual Consegna Pty Ltd Formulacion terapeutica bucal y/o sublingual.
EA201200054A1 (ru) 2009-06-25 2012-05-30 Эмпэр Лайф Сайнсиз, Инк. Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
HUE037592T2 (hu) * 2009-08-26 2018-09-28 Bioelectron Tech Corp Eljárások cerebrális ischemia megelõzésére és kezelésére
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EA201201374A1 (ru) * 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
KR101796340B1 (ko) 2011-02-18 2017-11-10 바이오링거스 아이피 엘엘씨 안정화된 활성제를 포함하는 생성물을 제조하는 방법 및 이를 포함하는 조성물
EP2720699B1 (en) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
RU2015120181A (ru) * 2012-11-13 2017-01-10 Гордаген Фармасьютикалз Пти Лтд Чресслизистая доставка токотриенола

Also Published As

Publication number Publication date
JP6978392B2 (ja) 2021-12-08
JP6460998B2 (ja) 2019-01-30
MY177940A (en) 2020-09-28
PL2919777T3 (pl) 2020-07-13
BR112015010703A2 (pt) 2017-07-11
US20150265570A1 (en) 2015-09-24
PT2919777T (pt) 2020-03-30
CA2891164C (en) 2021-02-09
SG11201503640WA (en) 2015-06-29
US10675265B2 (en) 2020-06-09
EP2919777A1 (en) 2015-09-23
AU2013344817A1 (en) 2015-02-12
CN112451518B (zh) 2025-02-21
ZA201504191B (en) 2016-11-30
BR112015010703A8 (pt) 2018-08-14
US20200246306A1 (en) 2020-08-06
DK2919777T3 (da) 2020-03-09
IN2015DN04006A (enExample) 2015-10-02
PE20151518A1 (es) 2015-11-25
RU2015120181A (ru) 2017-01-10
CN104582700B (zh) 2021-01-05
BR112015010703B1 (pt) 2021-02-17
WO2014075135A1 (en) 2014-05-22
JP2019031504A (ja) 2019-02-28
PH12015501048A1 (en) 2015-07-27
EP2919777A4 (en) 2016-05-18
CN104582700A (zh) 2015-04-29
EP2919777B1 (en) 2020-01-08
JP2016503407A (ja) 2016-02-04
ES2778065T3 (es) 2020-08-07
CA2891164A1 (en) 2014-05-22
KR20150082109A (ko) 2015-07-15
HK1207295A1 (en) 2016-01-29
US11331302B2 (en) 2022-05-17
NZ628963A (en) 2017-02-24
AU2013344817B2 (en) 2015-09-17
JP2021008509A (ja) 2021-01-28
CN112451518A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
ZA201504191B (en) Transmucosal delivery of tocotrienol
IL236268B (en) Preparations for mucosal administration and their uses
GB2503668B (en) Delivery apparatus
GB201213491D0 (en) Content delivery system
GB2507485B (en) Lead delivery apparatus
ZA201505049B (en) Transmucosal delivery of glatiramer acetate
EP2829537A4 (en) CHROME COMPOUND
SG10201609440WA (en) Multi-additive delivery system
PL2908837T3 (pl) Kompozycje do dostarczania leku
EP2911420A4 (en) CONTENTS ISSUE PROCEDURE
GB201218012D0 (en) Dosage forms
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
AU344424S (en) Nebulizer
EP2839418A4 (en) LOTTERY ADVERTISING
HUE047982T2 (hu) Szinterelt üvegtermék
HK40048338B (zh) 生育三烯酚的经粘膜递送
GB201208751D0 (en) Anti-malarial compounds
PH32012000655S1 (en) Sock
TWM433160U (en) Cup structure improvement
GB201216518D0 (en) Convienance cup
GB201210511D0 (en) Parcel delivery solution
AU346861S (en) Bracket
AU345987S (en) Bracket
GB201220136D0 (en) Anti-ligature Bracket
AU345981S (en) Bracket